Loading...
•
Mar 31, 2022
Adaptive Biotechnologies Q1 2022 Earnings Report
Adaptive Biotechnologies reported financial results for Q1 2022, showing a slight revenue increase and a strategic reorganization around MRD and Immune Medicine.
Key Takeaways
Adaptive Biotechnologies reported a slight increase in revenue for Q1 2022, with a strategic reorganization focusing on MRD and Immune Medicine. Total revenue reached $38.6 million, a 0.5% increase compared to Q1 2021. The company's net loss increased to $62.8 million, and operating expenses rose by 28%.
Revenue for Q1 2022 was $38.6 million, a 0.5% increase year-over-year.
clonoSEQ test volume grew 45% compared to Q1 2021 and 12% over Q4 2021.
MRD regulatory milestone revenue of $3.0 million was recognized.
A new T-MAP collaboration was established with Janssen to map T cell responses to RSV.
Revenue by Segment
Forward Guidance
Adaptive Biotechnologies reiterates full year 2022 revenue to be in the range of $185 million to $195 million.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...